FDA clears St. Jude's neurostimulation lead delivery system

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

St. Jude Medical has received FDA clearance and limited market release of its Epiducer lead delivery system for neurostimulation therapy.

The Epiducer lead delivery system reduces the need for multiple incisions typically required to place more than one neurostimulation lead utilized in spinal cord stimulation therapy for the management of chronic pain by allowing physicians to place multiple neurostimulation leads through a single entry point.

This minimally invasive system also enables physicians to deliver one, two or three different leads through a single entry point to configure and optimize the therapy for each patient. This allows for the management of complex and multifocal pain patterns such as low back pain combined with leg pain, according to the St. Paul, Minn.-based medical device company.